Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.

PloS one - 1 Jan 2012

Wu Xinqi, Zhu Meijun, Fletcher Jonathan A, Giobbie-Hurder Anita, Hodi F Stephen

Abstract excerpt

GNAQ mutations at codon 209 have been recently identified in approximately 50% of uveal melanomas (UM) and are reported to be oncogenic through activating the MAPK/Erk1/2 pathway. Protein kinase C (PKC) is a component of signaling from GNAQ to Erk1/2. Inhibition of PKC might regulate GNAQ mutation-induced Erk1/2 activation, resulting in growth inhibition of UM cells carrying GNAQ mutations. UM cells carrying wild...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bromodeoxyuridine
Share to Cell Cycle Checkpoints
Share to Cyclin-Dependent Kinase Inhibitor p27

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Screening Assays, Antitumor

Share to GTP-Binding Protein alpha Subunits

Share to GTP-Binding Protein alpha Subunits, Gq-G11

Share to Uveal Melanoma

Share to Uveal Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 22253748
DOI: 10.1371/journal.pone.0029622
PMCID: PMC3257235

Genes

GNAQ

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.PMID 22253748Read ↗

Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF-κB PathwaysSemantic proximity Read ↗

Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.Semantic proximity Read ↗

Targeting GNAQ/11 through PKC inhibition in uveal melanoma.Semantic proximity Read ↗

The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.Semantic proximity Read ↗

Protein kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation.Semantic proximity Read ↗

Functional characterization of uveal melanoma oncogenes.Semantic proximity Read ↗

Uveal melanoma: progress in molecular biology and therapeuticsSemantic proximity Read ↗

Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.Semantic proximity Read ↗

Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.Semantic proximity Read ↗

Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma.Semantic proximity Read ↗

Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071Semantic proximity Read ↗

[Uveal Melanoma: Molecular and Genetic Mechanisms of Development and Therapeutic Approaches].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.